Prudence Ive to Tuberculosis, Multidrug-Resistant
This is a "connection" page, showing publications Prudence Ive has written about Tuberculosis, Multidrug-Resistant.
Connection Strength
0,099
-
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
Score: 0,099